| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/07/1999 | EP0906959A2 Aminopeptidase from Staphylococcus aureus |
| 04/07/1999 | EP0906958A2 Staphylococcus peptidyl-tRNA hydrolase (Pth) |
| 04/07/1999 | EP0906957A2 Lgt polypeptide |
| 04/07/1999 | EP0906956A2 MurD from Streptococcus pneumoniae |
| 04/07/1999 | EP0906955A2 FtsY |
| 04/07/1999 | EP0906444A1 Genetically transfected human dendritic cells, their production and use, preferably as vaccines |
| 04/07/1999 | EP0906442A1 Generation of viral transfectants using recombinant dna-derived nucleocapsid proteins |
| 04/07/1999 | EP0906439A1 Polycistronic expression plasmid for tumor-rejection |
| 04/07/1999 | EP0906433A1 Protein tyrosine phosphatases of hematopoietic cells |
| 04/07/1999 | EP0906428A1 Use of interleukin-10 to produce a population of suppressor cells |
| 04/07/1999 | EP0906427A1 Characterization of transfer factors and methods of use |
| 04/07/1999 | EP0906426A1 Antibodies to the ed-b domain of fibronectin, their construction and uses |
| 04/07/1999 | EP0906425A2 Vasoactive amine binding molecules |
| 04/07/1999 | EP0906423A1 Metastasis-associated antigen and antibodies thereto |
| 04/07/1999 | EP0906417A1 Cross-linked protein crystal formulations and their use as catalysts in organic solvents |
| 04/07/1999 | EP0906337A2 AN ANTIGENIC EPITOPE OF THE u A /u DETERMINANT OF HEPATITIS B SURFACE ANTIGEN AND USES THEREOF |
| 04/07/1999 | EP0906335A1 Ebv ctl epitopes |
| 04/07/1999 | EP0906330A1 STREPTOCOCCUS PNEUMONIAE ISOLEUCYL tRNA SYNTHETASE |
| 04/07/1999 | EP0906110A1 Dna vaccine formulations |
| 04/07/1999 | EP0906019A1 LIVE ATTENUATED VACCINES BASED ON cp45 HPIV-3 STRAIN AND METHOD TO ENSURE ATTENUATION IN SUCH VACCINES |
| 04/07/1999 | EP0569531B1 Stabilized antibody fragments |
| 04/07/1999 | CN1213402A Recombinant expression of S-layer proteins |
| 04/07/1999 | CN1213380A Peptide immunogens for vaccination against and treatment of allergy |
| 04/07/1999 | CN1213326A Filtration of plasma mixtures using cellulose-based filter aids |
| 04/07/1999 | CN1213315A Compositions including calcium influx retardant for inhibiting cell growth |
| 04/07/1999 | CN1213312A Anticogulant agent useful in treatment of thrombosis |
| 04/06/1999 | US5892017 Recombinantly produced pf4ars are used in the preparation and purification of antibodies capable of binding to the receptors, and in diagnostic assays. the antibodies are advantageously used in the prevention and treatment of |
| 04/06/1999 | US5892001 Epithelium-derived T-cell factor antibodies |
| 04/06/1999 | US5892000 From hybridomas 2g6 and b14; for immunoassay test kit used in diagnosis of athlerosclerosis and diabetes |
| 04/06/1999 | US5891997 Receptor for oncostatin M |
| 04/06/1999 | US5891996 Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use |
| 04/06/1999 | US5891994 Peptides and polypeptides which induce antibodies against hiv-1 tat proteins; for vaccines; diagnosis |
| 04/06/1999 | US5891992 Processes for affecting in various ways the metabolism of animals using such modified peptides and vaccines |
| 04/06/1999 | US5891991 Aplp1 and aplp2 are candidate genes for late onset familial alzheimer's disease. |
| 04/06/1999 | US5891723 Large granular lymphocyte leukemia associated virus |
| 04/06/1999 | US5891716 An isolated nucleic acid comprising a nucleotide sequence encoding a peptide having at least one epitope recognized by a t cell receptor specific for allergen canis familiaris i or ii; medical diagnosis; antiallergens |
| 04/06/1999 | US5891705 Monomeric or oligomeric ethylenimine |
| 04/06/1999 | US5891700 Receptor-type phosphotyrosine phosphatase-γ |
| 04/06/1999 | US5891679 TNF-alpha muteins and a process for preparing them |
| 04/06/1999 | US5891678 Isolated polynucleotide encoding bacterial enzyme involved in mediating protein secretion; treatment of invasive infections and toxigenic diseases; antibiotic screening and development |
| 04/06/1999 | US5891677 Actinobacillus pleuropneumoniae outer membrane lipoprotein A and uses thereof |
| 04/06/1999 | US5891676 Recombinant molecule which contains baculovirus promoter spatially positioned with rotovirus protein vp2 gene; effective gene regulation; vaccine for animals and humans against diarrheal disease |
| 04/06/1999 | US5891672 Polynucleotides encoding GTP cyclohydrolase II (ribA) |
| 04/06/1999 | US5891670 Tetracycline resistance protein |
| 04/06/1999 | US5891667 SpoIIIe polynucleotides |
| 04/06/1999 | US5891664 Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR) |
| 04/06/1999 | US5891653 Immunomodulators for tissue transplants; contacting antigen presenting cells with purified stress proteins bound to an antigen; in vitro treatment of allograft, xenografts rejections in humans and animals |
| 04/06/1999 | US5891652 Methods of using domains of extracellular region of human platelet-derived growth factor receptor polypeptides |
| 04/06/1999 | US5891640 Peptide derived from human immunodeficiency virus type 1 (HIV-1), isolate ant70, containing an immunodominant epitope and it's use in immunodiagnostic assays |
| 04/06/1999 | US5891634 Transfection of enteric parasites |
| 04/06/1999 | US5891444 HIV-1 prophylactic composition and method |
| 04/06/1999 | US5891442 Containing foreign dna from infectious bursal disease virus |
| 04/06/1999 | US5891439 Lymphocyte stimulating factor |
| 04/06/1999 | US5891438 Method for stimulating production of variable region gene family restricted antibodies through B-cell superantigen vaccination |
| 04/06/1999 | US5891437 Antigen associated with type I diabetes mellitus |
| 04/06/1999 | US5891432 Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
| 04/06/1999 | US5891430 Diabetogene rad: a type II diabetes specific gene |
| 04/06/1999 | CA2107567C Detection of cardiovascular lesions |
| 04/06/1999 | CA2095836C Cytokine immunoconjugates |
| 04/06/1999 | CA2064705C Methods for culturing hcv in eukaryotic cells |
| 04/06/1999 | CA1340485C Peptide analogs and their use as haptens to elicit catalytic antibodies |
| 04/06/1999 | CA1340483C Diagnosis of retinoblastoma |
| 04/01/1999 | WO1999015692A2 Dengue virus antigens and treatment of dengue fever |
| 04/01/1999 | WO1999015690A1 Novel serratia marcescens strain, prodigiosin and the use of the same as an immunosuppressive |
| 04/01/1999 | WO1999015675A1 HUMAN COMPLEMENT C3-DEGRADING PROTEINASE FROM $i(STREPTOCOCCUS PNEUMONIAE) |
| 04/01/1999 | WO1999015672A1 Attenuated respiratory syncytial viruses |
| 04/01/1999 | WO1999015671A1 Hepatitis b virus polypeptides |
| 04/01/1999 | WO1999015670A1 LKTA DELETION MUTANT OF $i(P. HAEMOLYTICA) |
| 04/01/1999 | WO1999015669A2 Clostridium toxin, and method for preparing immunogenic compositions |
| 04/01/1999 | WO1999015666A2 Macrophage derived chemokine (mdc), mdc analogs, mdc inhibitor sustances, and uses thereof |
| 04/01/1999 | WO1999015657A2 53bp2 complexes |
| 04/01/1999 | WO1999015656A2 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 04/01/1999 | WO1999015654A2 Tie receptor tyrosine kinase ligand homologues |
| 04/01/1999 | WO1999015653A2 Tie ligand homologues |
| 04/01/1999 | WO1999015651A1 Synthetic polypeptide for diagnosing and treating prion-related diseases |
| 04/01/1999 | WO1999015631A1 Recombinant rsv virus expression systems and vaccines |
| 04/01/1999 | WO1999015628A1 Methods and compositions for binding hematopoietic stem cells |
| 04/01/1999 | WO1999015627A1 CELLULAR IMMUNOGENICITY POTENTIATING COMPOSITION CONTAINING α-GLYCOSYLCERAMIDE |
| 04/01/1999 | WO1999015553A2 Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use |
| 04/01/1999 | WO1999015205A1 Immunization against streptococcus pneumoniae using conjugated and unconjugated pneumococcal polysaccharide vaccines |
| 04/01/1999 | WO1999015201A1 Fucosyl gm1-klh conjugate vaccine against small cell lung cancer |
| 04/01/1999 | WO1999015200A1 MEDICINAL COMPOSITION CONTAINING gp34 BINDING INHIBITOR AS THE ACTIVE INGREDIENT |
| 04/01/1999 | WO1999015198A2 Agents for combating bacterial meningitis |
| 04/01/1999 | WO1999015190A1 Transgenic autologous t-cell therapy in humans, and related compositions and kits |
| 04/01/1999 | WO1999015162A2 Treatment and prevention of immunodeficiency virus infection by administration of non-pyrogenic derivatives of lipid a |
| 04/01/1999 | WO1999015154A1 Methods for fabricating polymer-based controlled release preparations |
| 04/01/1999 | WO1999004029A3 A swine hepatitis e virus and uses thereof |
| 04/01/1999 | WO1999004008A3 Cloned genomes of infectious hepatitis c viruses and uses thereof |
| 04/01/1999 | WO1999002564A3 Ancrod specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof and use of the same |
| 04/01/1999 | WO1999002545A3 Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
| 04/01/1999 | WO1999002186A3 Antigen delivery system comprising monoglyceride or diglyceride derivatives as adjuvant |
| 04/01/1999 | WO1999002182A3 Non-aqueous vaccines |
| 04/01/1999 | WO1998055615A9 Apaf-1, the ced-4 human homolog, an activator of caspase-3 |
| 04/01/1999 | WO1998053075A3 Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use |
| 04/01/1999 | WO1998052581A9 Vectors and methods for immunization or therapeutic protocols |
| 04/01/1999 | WO1998052573A9 Triterpene saponin analogs having adjuvant and immunostimulatory activity |
| 04/01/1999 | WO1998051787A3 Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety |
| 04/01/1999 | WO1998051321A9 Tissue factor for influencing blood vessel formation |
| 04/01/1999 | WO1998050554A3 Enterococcus faecalis polynucleotides and polypeptides |
| 04/01/1999 | WO1998044948B1 Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties |